Market Assessment, Type 2 Diabetes Current Treatment EU5 2017 Report

The type 2 diabetes market is expanding rapidly, fueled by increasing prevalence and a wave of recent product launches. Sanofi’s Suliqua (lixisenatide/insulin glargine), Novo Nordisk’s Fiasp, and AstraZeneca’s Glyxambi (linagliptin/empagliflozin) are examples of recent European product approvals. DRG believes the positive results from the EMPA-REGCVOT for Boehringer Ingelheim’s/Eli Lilly’s Jardiance will benefit uptake of the entire SGLT-2 inhibitor class. Current Treatment explores how the prescribing behaviors of European endocrinologists have changed in response to the rise of the SGLT-2 inhibitors and how other novel drugs compare.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Type 2 Diabetes | Current Treatment | EU5 | 2017

Related Market Assessment Reports

Renal Cell Carcinoma – Current Treatment – Detailed, Expanded Analysis: Treatment Sequencing (US)

Myasthenia Gravis – Current Treatment – Detailed, Expanded Analysis (US)

Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)